Myelin-associated inhibitors of axonal regeneration (MAG, Nogo, OMGP) (None)

Myelin-associated glycoprotein (MAG), Reticulon 4 (Nogo protein), and Oligodendrocyte myelin glycoprotein (OMGP) are three distinct, membrane-associated inhibitors of axonal regeneration in the central nervous system. They are major therapeutic targets for promoting nerve repair after CNS injury and contribute to the limited regenerative capacity of the adult mammalian CNS. They achieve this by converging on shared receptor systems, mainly the Nogo receptor (NgR1), and signaling pathways (notably Rho/ROCK). All three are being investigated for their roles in neurodegeneration, traumatic injury, and demyelinating diseases. While distinct molecules, they are often discussed together due to their common biological role and overlapping mechanisms of action in inhibiting CNS repair. The original query conflated these three distinct proteins into a single target, which is incorrect for precise scientific and therapeutic classification.

Other names

MAGNogo proteinReticulon 4Oligodendrocyte myelin glycoproteinMyelin-associated axonal growth inhibitors

MAG, Nogo (Reticulon 4), and Oligodendrocyte myelin glycoprotein (OMGP) primarily inhibit axonal regeneration in the central nervous system. They largely converge on shared receptor systems, mainly the Nogo receptor (NgR1), and activate downstream inhibitory signaling pathways, notably the Rho kinase (ROCK) pathway. MAG also binds to neuronal gangliosides (GD1a, GT1b), Nogo receptor 2 (NgR2), β1-integrin, and PirB.